Second Drug for Benign Synovial Tumor Condition Wins FDA Approval

(MedPage Today) -- The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant cell tumor (TGCT), a rare, non-malignant, but debilitating, condition arising in the synovium, the agency announced...